Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02950155 Active, not recruiting - Clinical trials for Generalized Myasthenia Gravis

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

Rinomax
Start date: October 16, 2016
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled multicenter study evaluating the safety and efficacy of Rituximab (Mabthera®) in patients with new onset generalized myasthenia gravis (MG).

NCT ID: NCT01105923 Active, not recruiting - Breast Cancer Clinical Trials

Study of an Intervention to Improve Problem List Accuracy and Use

MAPLE
Start date: May 2010
Phase: N/A
Study type: Interventional

The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians the opportunity to correct them. The investigators will randomize the clinics that will receive the intervention and formally evaluate the study after a period of 6 months for improved problem list completeness to determine the effectiveness of our intervention.

NCT ID: NCT00997412 Active, not recruiting - Myasthenia Gravis Clinical Trials

Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis

Myfortic
Start date: May 2009
Phase: N/A
Study type: Interventional

This is an randomized, double-blind, double-dummy trial, and the objective is to compare the efficacy and safety of Mycophenolic acid (MA) and Azathioprine (AZA), immunosuppressive drugs, in myasthenia gravis patients. This prospective study will enroll 40 myasthenia gravis (MG) patients who are poor controlled under prior steroid therapy. All subjects should be randomly assigned to MA group and AZA group that will receive routine pyridostigmine and prednisolone in combination with MA or AZA.

NCT ID: NCT00716066 Active, not recruiting - Myasthenia Gravis Clinical Trials

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.

NCT ID: NCT00294658 Active, not recruiting - Myasthenia Gravis Clinical Trials

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

Start date: June 2006
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.